Biognosys has entered a partnership with Alamar Biosciences to expand services and to research biofluid-based proteomics. The collaboration brings together Biognosys' DIA-MS (data independent acquisition mass spectrometry) expertise and Alamar's immunoassays, such as NULISA assays for low-abundance proteins such as cytokines, chemokines, and important disease protein biomarkers from plasma. A successful pilot study has already been conducted on Non-Small Cell Lung Cancer (NSCLC).
Biognosys AG is a Switzerland-based biotech company specializing in proteomics. The company uses patented high-resolution mass spectrometry technology for precise protein quantification to provide a view of protein expression, function, and structure across various sample types.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.